Scholars Central

Conference abstractPublished 24 Jun 2014

Non-RGD-based strategies to target the thyroid-αvβ3 integrin axis: Lesson from multiple myeloma

Authors: Keren Cohen

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: α v β 3 integrin is a cell surface receptor with a pivotal role in cancer, attaching proteins through an RGD (Arg- Gly-Asp) recognition site and acting as a true signaling molecule. Recently, a non RGD site, binding L-thyroxine (T4) and 3, 5, 3?-triiodo-L-thyronine (T3), has been described, initiating proliferative activities, mainly via the MAPK pathway. It has recently been shown that similar activation occurs in multiple myeloma (MM), a hematological disease with poor prognosis despite all approaches. This novel non RGD site can be blocked by tetraiodothyroacetic acid (tetrac), a natural deaminated T4 analog. In the present work, tetrac mechanism of action is characterized, for the first time in MM. Methods: MM cell lines (CAG, RPMI 8226,ARK, ARP-1, U266) and primary cells, were grown with T3/T4 with/without tetrac (100 nM-50 μ M) and analyzed for: cell counts (FACS, CyQuant), viability (WST-1), cell cycle (FACS, PI), cell death (Annexin- PI±pan-caspase inhibitor, ZVAD, FACS; cleaved Caspase 3, cleaved PARP, westerns), DNA damage response (pATM and PARP, westerns) and apoptotic genes (Real-Time PCR). Results: An early (4-8 hours) and late (24 hours) effect by tetrac was observed. In the early phase, tetrac reduced cell proliferation (p<0.05) and induced DNA damage response (ATM and PARP) and apoptosis (Cleaved caspase 3 and cleaved PARP). After 24 hours, tetrac reduced significantly (p<0.05) cell number and cell viability and induced apoptotic cell death with a parallel increase in apoptotic genes expression. Conclusion: The non RGD- α v β 3 integrin site in myeloma is a valid target for inhibition and examining potential blockers is pioneering

Subjects

Biology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Cell Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Cell Science & Therapy
  • SubjectBiology
  • BylineArticles whose byline prints “Keren Cohen”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels